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Abstract
Background: Humans are genetically defective in synthesizing the common mammalian sialic acid N-glycolylneuraminic
acid (Neu5Gc), but can metabolically incorporate it from dietary sources (particularly red meat and milk) into glycoproteins
and glycolipids of human tumors, fetuses and some normal tissues. Metabolic incorporation of Neu5Gc from animal-derived
cells and medium components also results in variable contamination of molecules and cells intended for human therapies.
These Neu5Gc-incorporation phenomena are practically significant, because normal humans can have high levels of
circulating anti-Neu5Gc antibodies. Thus, there is need for the sensitive and specific detection of Neu5Gc in human tissues
and biotherapeutic products. Unlike monoclonal antibodies that recognize Neu5Gc only in the context of underlying
structures, chicken immunoglobulin Y (IgY) polyclonal antibodies can recognize Neu5Gc in broader contexts. However, prior
preparations of such antibodies (including our own) suffered from some non-specificity, as well as some cross-reactivity with
the human sialic acid N-acetylneuraminic acid (Neu5Ac).
Methodology/Principal Findings: We have developed a novel affinity method utilizing sequential columns of immobilized
human and chimpanzee serum sialoglycoproteins, followed by specific elution from the latter column by free Neu5Gc. The
resulting mono-specific antibody shows no staining in tissues or cells from mice with a human-like defect in Neu5Gc
production. It allows sensitive and specific detection of Neu5Gc in all underlying glycan structural contexts studied, and is
applicable to immunohistochemical, enzyme-linked immunosorbent assay (ELISA), Western blot and flow cytometry
analyses. Non-immune chicken IgY is used as a reliable negative control. We show that these approaches allow sensitive
detection of Neu5Gc in human tissue samples and in some biotherapeutic products, and finally show an example of how
Neu5Gc might be eliminated from such products, by using a human cell line grown under defined conditions.
Conclusions: We report a reliable antibody-based method for highly sensitive and specific detection of the non-human
sialic acid Neu5Gc in human tissues and biotherapeutic products that has not been previously described.
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Introduction
Humans cannot synthesize the common mammalian sialic acid
N-glycolylneuraminic acid (Neu5Gc), due to an irreversible
mutation in the gene encoding Cytidine monophosphate (CMP)-
N-acetylneuraminic acid (Neu5Ac) Hydroxylase (CMAH) - the
enzyme responsible for conversion of CMP-Neu5Gc from CMP-
Neu5Ac. Thus, in comparison to our closest evolutionary relatives
such as chimpanzees and gorillas, human blood cells and serum
proteins lack Neu5Gc and accumulate an excess of the precursor
sialic acid Neu5Ac [1,2]. In keeping with this, normal humans have
variable and sometime very high amounts of circulating antibodies
directed against Neu5Gc [3–5]. Despite this, small amounts of
Neu5Gc have been found in cultured human cells (including human
embryonic stem cells) [6], and in certain tissue samples from
humans [4,7]. Larger amounts of Neu5Gc were also reported
earlier in human malignant tumors and in fetal tissues (reviewed in
refs. 2,4,8), and we have recently confirmed the presence of 1–3%
Neu5Gc in the glycans of some human tumors [9]. Likewise,
Neu5Gc has been detected in some biotherapeutic products derived
from animal cells and/or grown in animal serum-containing media
[10–18]. These findings were typically made using monoclonal or
polyclonal anti-Neu5Gc antibodies, and have been confirmed by
chemical analysis and mass spectrometry [4]. While mass
spectrometric analysis is more definitive, it is not practical for
routine laboratory use, nor is it sensitive enough in some situations.
Furthermore, mass spectrometry lacks the ability to carry out
detection in situ, on cell surfaces or on tissue sections.
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On the other hand, the anti-Neu5Gc antibodies used to date also
have limitations. Monoclonal antibodies can be highly specific for
certain Neu5Gc containing glycans, but do not have the ability to
detect Neu5Gc on other structurally-related or unrelated glycans
[19,20]. Thus, polyclonal antibodies raised in chickens (another
species that make an immune response to Neu5Gc) have been
traditionally used to detect Neu5Gc [21–30]. In an attempt to
improve specificity and reduce background reactivity, such
antibodies have been affinity-purified from whole egg IgY from
immunized chickens [21–23,25]. A few years ago, we made an
attempt to further improve the specificity of such antibodies by
additional modifications of the affinity procedures [4]. However,
even with such improved preparations we noted a small amount of
cross-reactivity with non-Neu5Gc-containing glycans. This was
particularly clear when we did immunohistochemical studies of
embryos and tissues from mice with an induced human-like genetic
defect in Neu5Gc production [31]. Despite the complete absence of
Neu5Gc in mass-spectrometric analyses in this well-defined
situation, we still saw some background reactivity in some of these
mouse tissues. The likely explanation for this appears to be a low
level of cross-reactivity with high densities of other sialic acids, such
as the human sialic acid N-acetylneuraminic acid (Neu5Ac). Thus,
there remains a need for a highly sensitive and specific method to
routinely detect Neu5Gc in all its presentation forms, in human
tissues and cells, as well as in biotherapeutic products intended for
human use. Here we remedy this deficiency using a new approach
that allows highly sensitive and specific detection of Neu5Gc with
applications in a variety of methodologies.
Materials and Methods
Chemicals, Reagents and Buffers
The sources of some reagents are listed within the method
descriptions below. The following materials were from the sources
indicated: Affi-Gel 15, Dowex AG50WX-2 and Dowex AG1X8,
Bio-Rad, Richmond, CA; N-glycolylneuraminic acid (Neu5Gc)
Inalco Pharmaceuticals, San Luis Obispo, CA; ExCellTM VPRO
medium, JRH biosciences; Isogel agarose isoelectric focusing (IEF)
plates, pH 3–10, Cambrex; Isoelectric Focusing Marker, Sigma;
Ureum, USB; Servalyt 3–7 ampholytes, Serva; 1,2-Diamino-4,5-
methylene-dioxybenzene (DMB), Cold Water Fish Skin Gelatin,
Tween-20, Sigma Chemical Co., St. Louis, MO, Sigma-Aldrich;
GlykoSep R high performance liquid chromatography (HPLC)
column, Glyko; Sialic Acid Reference panel, Glyko; Quantikine-
HIVDH Erythropoietin ELISA from R&D Systems Inc. Buffers
used were: Tris Buffered Saline (TBS) was prepared with 50 mM
Tris HCl, 150 mM NaCl, pH 8; TBST, TBS containing 0.1%
Tween-20; Phosphate buffered saline (PBS). Pairs of defined
glycan structures containing Neu5Ac or Neu5Gc attached to
polyacrylamide (PAA) were from Glycotech, and those attached to
human serum albumin (HSA) were prepared as previously
described [32].
Initial Preparation of Crude Chicken Polyclonal Antibody
Against Neu5Gc
Ganglioside Neu5Gca2-3Galb1-4G1cb1-1’Ceramide (GM3
(Neu5Gc)) was prepared from horse erythrocytes [33] and used
to immunize 2 Rhode Island Red chickens with 1 mg immunogen
in Freund’s complete Adjuvant containing 1 mg bovine serum
albumin (BSA), followed with boosts of 50 mg ganglioside in
incomplete Freund’s Adjuvant every three weeks. Eggs were
collected and the yolks kept at 4uC until used. Total IgY was
purified from the egg yolk by precipitating to 50% saturation with
ammonium sulfate. The pellet was suspended in PBS, and dialyzed
against PBS using 10,000 Molecular weight cut-off (MWCO)
tubing. The crude IgY prep was stored frozen until affinity
purification.
Preparation of Pre-clearing and Affinity Purification
Columns
The pre-clearing column was prepared by coupling pooled
human type AB serum sialoglycoproteins (PelFreez, Rogers, AR)
to Affigel-15 activated immunoaffinity support according to the
manufacturer’s instructions. The affinity column was prepared by
similarly coupling chimpanzee serum (obtained from Yerkes
National Primate Research Center) to Affi-Gel 15. For each
column, 10 ml of resin was washed with 30 ml of 50 mM Sodium
acetate pH 5.5, mixed with one ml of serum diluted to 14 ml of
100 mM 3-(N-morpholino)propanesulfonic acid (MOPS) pH 7.5,
and gently agitated overnight on an end-over-end mixer at 4uC.
Any remaining active esters were blocked by the addition of 1 ml
of 1 M Ethanolamine and continued mixing for one hour. The
resin was poured into a glass column and washed with 3 column
volumes of 50 mM Sodium acetate pH 5.5. The sialic acid content
of bound glycoproteins was determined by performing mild acid
hydrolysis (0.18 N H2SO4 for 1 hour at 80uC followed by
neutralization with NaOH) on an aliquot of each resin, and by
performing the thiobarbituric acid (TBA) assay on the superna-
tants containing the released sialic acids.
Pre-clearing of the IgY pool and Isolation of the anti-
Neu5Gc specific antibodies
The crude immune IgY preparation was applied to the human
serum Affi-Gel 15 pre-clearing column and allowed to run
through. The effluent was collected and reapplied to the same
column to allow for maximum binding of any non-specific or
Neu5Ac-recognizing IgY antibodies to the Neu5Ac-containing
human serum glycoproteins. The column was then washed with
10 ml of PBS, pH 7.4 and the washes combined with the column
effluent. The pooled washes were applied onto the chimpanzee
serum affinity column, the effluent collected and reapplied to the
same column to allow for maximum binding of anti-Neu5Gc
antibodies. The column was washed with 50 ml of PBS, pH 7.4,
and the specific antibody then eluted from the resin using 5 mM
Neu5Gc in PBS, pH 7.4. The first 5 ml of the eluting buffer was
added to the column and allowed to run through. The column was
then closed off, a second 5 ml of the eluant added (to prevent the
column from drying out) and allowed to stand overnight, for a
more complete elution of the antibody from the column. The
following day, 11 additional 5 ml fractions were collected, by
washing with the same eluant. The Neu5Gc-reactive fractions
were detected by ELISA, using Costar high-binding plates coated
in alternating rows with either 2.5 mg per ml of Neu5Gc or
Neu5Aca-PAA-Biotin (Glycotech) or with 1 ml of Bovine or
Human serum in 100 ml of 50 mM sodium carbonate-bicarbonate
buffer, pH 9.5 at 4uC overnight. The wells were washed with TBS
pH 7.5 followed by blocking with 200 ml of TBST at room
temperature for 1 hr. For the identification of anti-Neu5Gc
positive fractions, 100 ml aliquots of dilutions of the eluted affinity
column fractions were added to each well and incubated at room
temp for 2 hr. The wells were washed with TBS pH 7.5 followed
by the addition of 100 ml of a 1:10,000 dilution of Donkey anti-
chicken IgY-horseradish peroxidase (HRP) (Jackson ImmunoR-
esearch) in TBST and incubated at room temp for 1 hr. The wells
were washed and developed using 140 ml of a developing solution
(20 ml of citrate phosphate buffer, pH 5.5, 10 mg of O-
phenylenediamine (OPD), 50 ml of 30% hydrogen peroxide).
Detection of Non-Human Sia
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Once adequate color had developed, the reaction was quenched
with 40 ml of 4 M Sulfuric acid, and the absorbance was read at
490 nm.
Fractions that were positive for anti-Neu5Gc antibodies were
pooled and concentrated to 0.5 ml using an Amicon Ultrafree-15
10,000 molecular weight cut-off centrifugal filter device. To
reduce the concentration of free Neu5Gc in antibody solution,
15 ml of PBS, pH 7.4 was added to the filtration device and the
sample concentrated again to 0.5 ml. This process was repeated
two more times until the concentration of the Neu5Gc was
reduced to about 20 mM, a concentration too low to affect
antibody binding in any studies. A typical protein concentration of
the purified antibody was 5–9 mg/ml. After the elutions, both the
Human serum and Chimp serum Affi-Gel 15 columns were
washed with 50 ml of PBS, pH 7.4 followed by cleaning with
50 ml of 0.1 M Citric Acid pH 3.0, and immediately washed
again with 50 ml of PBS, pH 7.4 to neutralize the acid. The
columns were stored in PBS, pH 7.4 containing 0.5% Sodium
azide for future use.
ELISA Analysis for Neu5Gc Specificity of the Affinity-
purified IgY Antibody
Anti-Neu5Gc antibody reactivity was detected by ELISA as
previously described [5]. Briefly, we used 96-well microtiter plates
(Costar) coated in triplicates with optimized buffers and saturating
concentrations of various pairs of Neu5Ac- and Neu5Gc-
glycoconjugates as follows: GM3 ganglioside in methanol
(50 pmole sialic acid/well); Neu5Gc/Aca-PAA-Biotin (250 ng/
well) and Neu5Gc/Ac2-3/6Lac-HSA-Biotin (1 mg/well); ovine
submaxillary mucin (OSM) and porcine submaxillary mucin
(PSM) (100 pmole sialic acid/well), and bovine submaxillary
mucin (BSM) or base-treated BSM (190 pmole sialic acid/well) in
50 mM sodium carbonate-bicarbonate buffer, pH 9.5. Pairs of
Neu5Gc/Aca2-6GalNAc-HSA-Biotin (1 mg/well), 9-OAc-
Neu5Gc/Aca2-6GalNAc-HSA-Biotin (1 mg/well), in 50 mM
sodium phosphate buffer, pH 7.5 (an optimal pH for preserving
O-acetylation of sialic acid). In addition, we coated wells with
Human or Bovine Fibrinogen (Sigma, St Louis, MO) (0.5 mg/
well), serum from C57BL/6 wild-type or Cmah2/2 mice, human
or chimpanzee serum (diluted 1:1,000/well). Methanol was
allowed to evaporate completely for 4 hours at room temperature
(RT) and plates were incubated overnight at 4uC. Wells were
blocked for 1 hours at RT with 1% ovalbumin (Sigma, St Louis,
MO; Grade V, free of Neu5Gc) in PBS, followed by incubation
with affinity purified chicken anti-Neu5Gc diluted 1:10,000 in the
same blocking solution for 2 hours at RT. The plates were washed
three times with PBS containing 0.1% Tween (PBST) and
subsequently incubated for 1 hour at RT with HRP-conjugated
donkey-anti-chicken IgY diluted in PBS (1:10,000; Jackson
ImmunoResearch, West Grove, PA). After washing three times
with PBST, wells were developed with O-phenylenediamine in
citrate-PO4 buffer, pH 5.5, and absorbance was measured at a
490 nm wavelength on a SpectraMax 250 (Molecular Devices).
Neu5Gc-specific antibody levels were defined by subtracting the
readings obtained with the Neu5Ac-glycoconjugates from the
readings obtained using the respective Neu5Gc-glycoconjugates
(in the case of naturally-occurring molecules containing Neu5Gc,
the background subtracted was that of triplicate wells containing
only the respective buffer).
Western Blot Analysis
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) separated proteins were transferred to nitrocellulose
membranes following standard procedures. Membranes were
blocked overnight at 4uC with 0.5% gelatin from cold water fish
skin (Sigma) in TBST, and then incubated at room temperature
for 2 hr with affinity purified chicken anti-Neu5Gc diluted
1:100,000 with TBST or with a control non-specific Chicken
IgY antibody pool (Jackson ImmunoResearch) at the same protein
concentration. The membranes were washed again with TBST
and then incubated with Donkey anti-chicken HRP (Jackson
ImmunoResearch) 1:50,000 in TBST at room temperature for
1 hr. The membranes were washed and incubated with Pierce
SuperSignal West Pico Substrate (Pierce) as per manufacturer’s
recommendation, exposed to X-ray film and the film developed.
Flow Cytometry Analysis
The blocking solution used for all the analysis, manipulations
and dilutions was 0.5% cold water fish skin gelatin in PBS, pH 7.3
containing 1 mM ethylenediaminetetraacetic acid (EDTA). Chi-
nese hamster ovary-K1 (CHO-K1) cells were detached from the
tissue culture dish using 10 mM EDTA in PBS, pH 7.3 for 5 to
10 min. The cells were immediately washed in blocking buffer
containing 5 mM EDTA and counted. Peripheral blood mono-
nuclear cells (PBMCs) were prepared by standard Ficoll-Paque
Plus protocol, and washed in blocking buffer. Once prepared,
16106 cells were used for each staining. All staining reactions were
performed at 4uC. The cell pellet was gently resuspended in 100 ml
of either affinity purified chicken anti-Neu5Gc antibody or control
pre-immune IgY diluted 1:4000 in blocking solution and
incubated on ice for 1 hr. The cells were washed with 1 ml of
blocking buffer, mixed gently, and pelleted at 5006g for 5 min.
The cells were suspended in 100 ml Cy5-conjugated Donkey-anti-
chicken IgY antibody, diluted 1:4000 in blocking buffer, incubated
on ice for 1 hr, and washed as above. Stained cells were suspended
in 400 ml PBS, the data collected on a FACSCalibur (BD
Biosciences Immunocytometry Systems, San Jose, CA) and
analyzed with Flowjo software (Tree Star, Ashlan, OR).
Immunohistochemical Analysis
Frozen sections or paraffin sections of wild type mouse embryos,
or wild type adult mouse organs, along with similar sections from
CMAH null tissues, were used initially to confirm specificity of
antibody binding to Neu5Gc containing tissues, with no binding
seen to the CMAH null tissues (collection of mouse tissues from
euthanized animals adhered to UCSD institutional guidelines for
the ethical treatment of animals). When studying human tissues,
frozen sections or paraffin sections of human placenta were always
used as positive controls, because staining of endothelial cells lining
blood vessels was the control necessary for interpretation of
staining on other tissues. The anti-Neu5Gc antibody or Chicken
IgY concentrations used on human sections were each at ,5
micrograms per ml on frozen or on paraffin sections (1:1000 or
1:500 respectively - when detecting larger amounts of Neu5Gc in
animal tissues it is possible to use dilutions of 1:10,000 or
1:20,000). The frozen sections were air-dried, and washed in
phosphate buffered saline with 0.1% Tween (PBST) and overlaid
with blocking buffer (0.1% fish gelatin in PBST). The washes were
performed between each step and the blocking buffer was used for
dilution of each of the reagents that were overlaid onto the tissue
sections. The slides were incubated in a humid chamber with
parafilm on them, to prevent drying during the incubation steps.
The sections were blocked for endogenous biotin, overlaid with
primary reagents, the binding of which was detected using a
secondary biotinylated secondary, and a labeled streptavidin.
If paraffin sections were used in an immunohistochemistry
assay, the slides were de-paraffinized before proceeding with the
steps outlined above. Slides were immersed in 3 changes of xylene
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for 10 minutes each to remove the wax, followed by rehydration in
decreasing concentrations of alcohol, before submersion in buffer.
Following the biotinylated secondary antibody enhancement steps
using the DAKO CSA kit (which uses the biotinyl tyramide
amplification method) was used. We also found that following
incubation with the primary reagents, specific binding could be
detected using a secondary rabbit anti-chicken antibody (Jackson
ImmunoResearch), followed by a fluorescently or enzyme labeled
tertiary anti-rabbit antibody (Jackson ImmunoResearch). When
Horse Radish Peroxidase (HRP) was the label, endogenous
peroxidases were blocked before proceeding with the other steps
and color was developed using peroxidase substrates (Vector labs)
following manufacturer’s recommendations, and nuclei were
counterstained using Mayer’s hematoxylin before coverslipping
using aqueous mounting media. If fluorescent labels were used, the
slides were mounted in aqueous mounting media and viewed using
epifluorescence with a Zeiss Axiophot microscope, digital images
were captured using the Scion NIH image program and analyzed
using Adobe Photoshop. With the color read-out, digital images
were captured on an Olympus BH2 microscope, using the
Magnafire digital photocapture program.
Results and Discussion
The affinity purified chicken anti-Neu5Gc antibody is
stable under a variety of conditions
A polyclonal monospecific chicken anti-Neu5Gc antibody was
prepared as described in ‘‘Materials and Methods’’ by sequential
application to a pre-clearing column of immobilized human serum
sialoglycoproteins (glycosidically-bound Neu5Ac only, in various
linkages) followed by a column of immobilized chimpanzee serum
sialoglycoproteins (glycosidically-bound Neu5Ac and Neu5Gc in
approximately equal amounts, in various linkages). Specific elution
of the antibodies using Neu5Gc from the second column was
followed by simultaneous concentration and reduction of the free
Neu5Gc to insignificant levels. The activity of the final chicken anti-
Neu5Gc antibody preparation was assayed for stability to pH,
freeze-thaw and lyophilization, using 1 hr or 3 hr incubations at
4uC in various buffers and pH’s. The activity (as determined by
ELISA against Neu5Gca-PAA) remained intact in pH ranges of 4–
10 and was highest in 100 mM Sodium acetate pH 4. However a
58% loss of activity was observed when the antibody was incubated
in 100 mM Citrate buffer pH 3.0 (note that prior attempts at
affinity chromatography typically eluted such IgY antibodies under
such low pH conditions). There was no loss of ELISA reactivity after
10 rounds of lyophilization at pH 7.3. Storage at room temperature
for 3 days after lyophilization also did not appreciably reduce the
activity in most assays. The antibody was also stable to extended
storage at 4uC in PBS pH 7.3 for 6–8 weeks in various protein
concentrations. There was an appreciable loss of activity when the
protein concentration dropped below 60 mg/ml but not when the
protein concentration was kept in the range of 0.6–6 mg/ml.
Prolonged storage at 4uC or repeated freeze-thaw can result in some
background reactivity with the control IgY, likely due to formation
of aggregates. In addition, prolonged 4uC storage of the
reconstituted lyophilized antibody somewhat diminished its binding
capacity in immunohistochemistry.
Affinity-purified antibody recognizes Neu5Gc with
various linkages to underlying glycans
Sialic acids can be bound to underlying glycans by a2-3, a2-6, or
a2-8 glycosidic linkages. Presumably because the binding pocket of
antibodies can accommodate .4 monosaccharides [34–37], all
mouse and chicken monoclonal Neu5Gc-dependent antibodies
reported to date show specificity for both the sialic acid linkage and
the precise structure of the underlying glycan chain [19,20]. Despite
the fact that the primary immunogen used to immunize chickens
(GM3-Neu5Gc) contained Neu5Gc only in the a2-3linkage, the
final antibody preparation reacted with all linkages and underlying
glycan structures tested. A likely explanation is that the BSA that is
traditionally used as a carrier is contaminated with Neu5Gc-
containing bovine serum sialoglycoproteins (our unpublished
observations). Regardless of the reason, this broad specificity was
found both with synthetically prepared compounds (Figure 1A) and
with naturally-occurring molecules containing Neu5Gc (Figure 1B).
Even O-acetylation of the glycerol-like side chain of sialic acid, such
as that found in Bovine submaxillary mucin (BSM) did not block
recognition, as reactivity was not altered by prior de-O-acetylation
of BSM by base treatment (Figure 1B). These results are typical of
many ELISAs done with Neu5Gc-containing molecules. We have
so far not encountered any instance where the antibody did not
detect such molecules.
In every case tested, there was little or no reactivity with the
Neu5Ac-containing counterpart (data not shown), confirming the
extreme specificity of the antibody for the single oxygen atom that
differs between Neu5Gc and Neu5Ac. This contrasts with prior
methods of preparing chicken polyclonal anti-neu5Gc antibodies
(including ours), which showed varying degrees of cross-reactivity
with Neu5Ac-containing epitopes, as well as other non-specific
reactivity. This improvement likely resulted from both the pre-
clearing step using immobilized human serum sialoglycoproteins
(containing only Neu5Ac), and from the specific elution by
Neu5Gc from the Neu5Gc-containing immobilized chimpanzee
serum sialoglycoproteins. The pre-clearing using human proteins
also helped to eliminate other non-specific cross-reactivities when
studying human tissue samples. To further ensure specificity, all
subsequent studies used a commercial pooled batch of IgY as a
control, which showed no anti-Neu5Gc reactivity.
Sensitive and specific detection of Neu5Gc on
glycoproteins by Western blotting
Human serum and bovine serum proteins were electrophoresed
on 10% SDS-PAGE gels and transferred onto nitrocellulose
membranes as described in the Methods. While human serum did
not react at all with the antibody, the lane for bovine serum shows
a full spectrum of positive bands (Figure 2, lane A). Sialidase
pretreatment of the bovine serum abolished almost all reactivity
confirming the specificity for sialic acids (Figure 2, lane B). There
was no background staining seen when probing the blot with the
control IgY antibody, nor with secondary antibody alone (data not
shown). Thus, this antibody preparation can detect a complex
mixture of Neu5Gc-containing proteins in a specific manner.
Bovine fetuin was also used for a sensitivity check, as it carries a
variety of different sialic acid linkages and but only a low amount
of Neu5Gc (,2% of total sialic acids). Low mg amounts of fetuin
and asialofetuin were electrophoresed into a 10% SDS-PAGE gel.
Only the fetuin gave positive reactions, giving detection of as little
as 4 pmoles Neu5Gc contained in 1 mg of protein (Figure 2). This
is more sensitive than conventional detection of Neu5Gc by DMB-
derivatization and HPLC analysis with fluorescent detection [38]
(previously the most sensitive method, with a detection limit of
,10–20 pmoles, depending on the background).
Sensitive and specific detection of Neu5Gc on cell
surfaces by flow cytometry
Flow cytometry of various cell types was carried out as described
in Methods. While human PBMCs, which do not express Neu5Gc
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gave no significant signal, CHO cells which express only 2–3%
Neu5Gc gave a clear positive signal (Figure 3). Mouse PBMCs,
which express higher levels of Neu5Gc gave the highest signal
(data not shown.) None of these cells had any background staining
when incubated with the control IgY antibody, nor with secondary
antibody alone (data not shown). Thus the antibody is sensitive
and specific for Neu5Gc in flow cytometry analysis and is capable
of picking up very low levels of cell surface Neu5Gc.
Sensitive and specific detection of Neu5Gc by
immunohistochemistry in mouse and human tissues
Immunohistochemistry studies of various human and mouse tissue
sections were carried out as described in Methods, with the control
IgY in comparison. A few examples of the results are shown in
Figure 4. Whole embryos and multiple adult organs from wild-type
mice showed strong staining, whereas those from Cmah-null mice
showed no staining (Figure 4A). This improves on our earlier work,
Figure 1. Affinity purified Chicken IgY antibody recognizes Neu5Gc with various linkages to underlying glycans. A. Detection of
Neu5Gc on synthetic and semi-synthetic molecules. Reactivity of the affinity-purified anti-Neu5Gc antibody was tested in triplicate, by ELISA against
synthetic and semi-synthetic Neu5Gc- and Neu5Ac-target pairs, using Neu5Ac-glycans for background subtraction (the Neu5Ac A490 value was
subtracted from the corresponding Neu5Gc A490 value). B. Detection of Neu5Gc on natural glycoproteins. The affinity-purified anti-Neu5Gc antibody
was tested in triplicates by ELISA, against natural glycoproteins containing Neu5Gc and Neu5Ac, using buffer only for background subtraction. Error
bars indicate the standard deviation of triplicates. Gc, alpha-linked Neu5Gc; GM3, GM3 ganglioside; HSA, Human serum albumin; PAA,
polyacrylamide; and, SPG, sialylparagloboside.
doi:10.1371/journal.pone.0004241.g001
Detection of Non-Human Sia
PLoS ONE | www.plosone.org 5 January 2009 | Volume 4 | Issue 1 | e4241
which used a version of the chicken polyclonal antibody that was not
as rigorously purified, which showed some non-specific reactivity with
the Cmah-null mouse tissues [31]. Studies of normal human placenta
showed easily detectable staining within the endothelia of blood
vessels (4B). Most normal human tissues studied using frozen or
paraffin sections, consistently showed staining of the blood vessels,
and sometimes also of the glandular epithelial cells of breast, luminal
edge of colonic mucosal epithelial cells, crypt epithelium of small
intestine, some glandular epithelium of prostate, kidney glomeruli
and interstitial capillaries and lung bronchial epithelium (some
examples are shown in Figure 4C). Many malignant tumors and the
angiogenic blood vessels also showed staining with the anti-Neu5Gc
antibody (breast carcinoma, prostate carcinoma, ovarian carcinoma),
while some like melanoma and neuroblastoma, only showed staining
of blood vessels. In general, staining of paraffin-embedded sections of
the same samples showed primarily staining of blood vessels and not
much else, likely due to the extraction of glycolipids during the
embedding procedure. Staining could also be enhanced using a
rabbit anti-chicken antibody followed by a labeled anti-rabbit
antibody (both from Jackson ImmunoResearch) if needed. In no
case did any of the tissue sections show obvious background staining
when incubated with the control IgY antibody, nor with secondary
antibody alone. Thus the new antibody is sensitive and specific for
Neu5Gc in immunohistochemical analyses. Additional examples can
be seen in a recent study from our lab, where we used the antibody to
confirm the presence of Neu5Gc on normal human colon and kidney
samples [7].
Figure 2. Sensitive and specific detection of Neu5Gc-contain-
ing glycoproteins by Western Blot Analysis. Standard proteins
were run on a 10% SDS-PAGE gel and transferred onto nitrocellulose
membrane. The membrane was blocked overnight at 4uC with Neu5Gc-
free 0.5% gelatin from cold water fish skin (Sigma) in TBST. The
membranes were incubated at room temperature for 2 hr with the
affinity-purified chicken anti-Neu5Gc diluted 1:100,000 with TBST. The
membranes were washed with TBST and then incubated with Donkey
anti-chicken HRP (Jackson ImmunoResearch) 1:50,000 in TBST at room
temperature for 1 hr. The membranes were washed and incubated with
Pierce Super-Signal West Pico Substrate (Pierce) as per manufacturer’s
recommendation, exposed to X-ray film and the film developed. A,
bovine serum 1 mg; B, bovine serum 1 mg+sialidase; C, human serum; D,
blank lane. E–H, bovine fetuin 10, 5, 2, 1 mg. The smallest amount of
bovine fetuin contained only 4 pmoles of Neu5Gc per mg of protein as
determined by DMB-HPLC.
doi:10.1371/journal.pone.0004241.g002
Figure 3. Sensitive and specific detection of Neu5Gc on cells by
flow cytometry. CHO-K1 cells were detached from the tissue culture
dish using 10 mM EDTA in PBS, pH 7.3. The cells were immediately
washed in blocking buffer (0.5% gelatin from cold water fish skin in PBS,
pH 7.5) containing 5 mM EDTA and counted by hemocytometer.
Peripheral blood mononuclear cells (PBMCs) were isolated with Ficoll
Paque Plus (GE Healthcare), washed in blocking buffer and counted.
16106 cells were used for each staining which was done at 4uC. The
cells were washed with 1 ml cold blocking buffer then pelleted at
5006g for 5 min. The supernatant was carefully removed and
discarded. The cell pellet was gently suspended in 100 ml of either
affinity purified chicken anti-Neu5Gc antibody or control non-specific
IgY antibody diluted 1:4000 in blocking solution and incubated on ice
for 1 hr. The cells were washed by adding 1 ml of blocking buffer,
mixed gently, and pelleted as above. The cell pellet was gently
suspended in 100 ml Donkey-anti-chicken IgY Cy5-conjugated diluted
1:4000 in blocking buffer and incubated on ice for 1 hr. The cells were
washed as above, resuspended in 400 ml PBS, analyzed on a
FACSCalibur (BD Biosciences Immunocytometry Systems, San Jose,
CA) and the data analyzed using Flowjo software (Tree Star, Ashlan, OR).
Human PBMCs were negative for Gc (bottom), while mouse PBMCs
(data not shown) and CHO cells were positive for Gc (top). The gray
peak represents cells stained with total IgY of un-immunized chickens,
and the black trace represents cells stained with anti-Neu5Gc.
doi:10.1371/journal.pone.0004241.g003
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Detection of Neu5Gc in some FDA-approved
biotherapeutic antibodies
Biotherapeutic monoclonal antibodies were electrophoresed on
12.5% SDS-PAGE gels and transferred onto nitrocellulose
membranes as described in the Methods. Representatives of
biotherapeutic monoclonal antibodies studied were all IgG1
molecules: either chimeric or humanized mouse monoclonal
antibodies. There was no background staining seen in the blot
neither with the control IgY antibody, nor with secondary
antibody alone (data not shown). The anti-Neu5Gc antibody gave
Figure 4. Sensitive and specific detection of Neu5Gc in mouse and human tissues by immunohistochemistry. A. Direct scan of glass
slides with frozen sections of mouse embryos d16.5 or paraffin sections of adult mouse tissues, and detected using biotinylated anti-chicken antibody
followed by HRP-Streptavidin. B. Frozen sections of Human Placenta immunostained with primary reagents at 1:1000 each (5 ug/ml each) and
detected using biotinylated anti-chicken antibody, followed by HRP-Streptavidin (top) or CY3-Streptavidin (bottom). (4006magnification) C. Frozen
sections of normal human tissues immunostained with primary reagents at 1:1000 each (5 ug/ml each) and detected using biotinylated anti-chicken
antibody, followed by HRP-Streptavidin. (4006 magnification) D. Frozen sections of examples of human tumors immunostained with primary
reagents at 1:1000 each (5 ug/ml each) and detected using biotinylated anti-chicken antibody, followed by HRP-Streptavidin (4006magnification). E.
Frozen sections of human ovarian carcinoma immunostained with primary reagents at 1:1000 each (5 ug/ml each) and detected using biotinylated
anti-chicken antibody, followed by HRP-Streptavidin (top) or CY3-Streptavidin (bottom) (2006magnification).
doi:10.1371/journal.pone.0004241.g004
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staining on all these glycoprotein biotherapeutic agents (Figure 5,
lane C–G) most likely representing Neu5Gc originating from the
mammalian expression system used and/or animal-derived serum
or growth medium additives. Human IgG antibodies and human
and bovine serum were used as controls (Figure 5; A, J, L).
Interestingly, even some human sera gave a faint band, which
might be explained by incorporation of exogenous Neu5Gc into a
specific human serum glycoprotein.
The content of Neu5Gc in the biotherapeutic agents was also
measured by DMB-derivatization and HPLC analysis with
fluorescent detection, and the results were found to range from
undetectable levels up to 0.6 pmole of Neu5Gc per microgram
protein in the highest instance. Thus, using this anti-Neu5Gc IgY
antibody preparation in Western blotting appears to be more
sensitive than DMB-derivatization followed by HPLC fluorescent
analysis, and is likely detecting even smaller amounts of Neu5Gc
on FDA-approved biotherapeutic agents.
Lack of Neu5Gc in a biotherapeutic agent prepared in
the human PER.C6H cell line under Neu5Gc-free/serum-
free conditions
As previously reported by us and others, the presence of
Neu5Gc on biotherapeutic agents is very likely due to the use of
animal cells expressing Neu5Gc and/or the uptake of Neu5Gc
from animal derived serum culture media components. To prove
this conclusively, we used human cells in defined media to prepare
a biotherapeutic agent. PER.C6H cells were generated from
retina-derived primary human cells, which were immortalized by
insertion of the adenovirus E1 gene [39]. PER.C6H cells are a
Figure 5. Detection of Neu5Gc on Some FDA-Approved
Biotherapeutic Antibodies. Biotherapeutic agents, human IgG
(Jackson Immunoresearch), human serum and bovine serum samples
were run on a 12.5% SDS-PAGE gel and transferred onto a nitrocellulose
membrane. The membrane was blocked overnight at 4uC with 0.5%
gelatin from cold water fish skin (Sigma) in TBST. The membranes were
incubated at room temperature for 2 hr with the affinity-purified
chicken anti-Neu5Gc diluted 1:100,000 in TBST with 0.5% gelatin from
cold water fish skin or with a control non-specific Chicken IgY antibody
pool (Jackson ImmunoResearch) at the same protein concentration. The
membranes were washed with TBST and then incubated with Donkey
anti-chicken HRP (Jackson ImmunoResearch) 1:50,000 in TBST with 0.5%
gelatin from cold water fish skin and 1% human serum at room
temperature for 1 hr. The membranes were washed again and
incubated with Pierce SuperSignal West Pico Substrate (Pierce) as per
manufacturer’s recommendation, exposed to X-ray film and the film
developed. A, human IgG 1 mg; B, blank lane; C–G, 10 mg each of
various FDA-approved biotherapeutic IgG molecules; H and I, blank
lanes; J, human serum, 1 mg; K, blank lane; L, bovine serum, 1 mg.
doi:10.1371/journal.pone.0004241.g005
Figure 6. Lack of Neu5Gc in a biotherapeutic agent prepared in
the human PER.C6H cell line under Neu5Gc-free/serum-free
conditions. PER.C6H cells were stably transfected with cDNA encoding
human EPO and co-transfected with ST3GalIV for full sialylation of the
glycans of EPO. EPO-expressing PER.C6H cells were cultured under
serum-free conditions (VPRO medium) and EPO was purified from the
medium. The sialic acid content of PER.C6H-rEPO and of CHO-rEPO
(Eprex) was similar as determined by IEF (data not shown). A. The
presence of Neu5Gc on CHO-rEPO (Eprex) or PER.C6H-rEPO was
examined by DMB-HPLC according to [38]. B. The presence of Neu5Gc
on both CHO-rEPO (Eprex) and PER.C6H-rEPO was examined by the
highly sensitive Western blot as described in the Methods. 1 and 2 mg
of EPO and 5 mg of positive control (bovine fetuin) were run on a 4–
12% SDS-PAGE gel and blotted onto nitrocellulose membrane.
Immunostaining for Neu5Gc was performed as described in the
Methods and as above under figure 2.
doi:10.1371/journal.pone.0004241.g006
Detection of Non-Human Sia
PLoS ONE | www.plosone.org 8 January 2009 | Volume 4 | Issue 1 | e4241
versatile platform suitable for the production of vectors for gene
therapy [40], vaccines [41] and therapeutic glycoproteins such as
monoclonal antibodies [42,43]. As part of further evaluation of
PER.C6H cells as a platform for the production of therapeutic
glycoproteins these cells were stably transfected with cDNA
encoding human erythropoietin (EPO) and co-transfected with a
human a2-3sialyltransferase (ST3GalIV) to ensure full sialylation
of the glycans of EPO. Transfection, selection and adaptation to
serum-free media were performed as described before [42,43].
The expression plasmid contained the coding sequences for
human EPO and human ST3GalIV, both driven by a cytomeg-
alovirus (CMV) promoter that has been modified to achieve high
levels of gene expression in PER.C6H cells. An EPO ELISA kit
was used to screen for the cell lines with highest expression levels.
EPO-expressing PER.C6H cells were cultured under serum-free
conditions (VPRO medium) and EPO was purified from the
medium by affinity chromatography and ion-exchange chroma-
tography. The sialic acid content of PER.C6H-recombinant
erythropoietin (rEPO) and of Eprex (CHO-rEPO, Janssen Cilag)
was found to be similar as determined by isoelectric focusing (IEF).
The presence of Neu5Gc on both EPO samples was examined by
HPLC following 1,2-diamino-4,5-methylene-dioxybenzene (DMB)
derivatization, according to [38], and by the highly sensitive
Western blot as described in the Methods. In contrast to EPO-
derived from CHO cells (Eprex) the PER.C6H-rEPO did not
contain sialic acid in the Neu5Gc form, as is expected for a
product from a human cell line (Figure 6).
Humans are known to have circulating antibodies against
galactosea1-3-galactose (aGal) and the presence of this epitope on
biotherapeutics can cause adverse events [44]. It is now clear that
some humans can have similarly high levels of circulating
antibodies against Neu5Gc [5]. The use of a human production
platform such as PER.C6H cells may avoid problems caused by the
presence of non-human glyco-epitopes, since these are absent from
biotherapeutics produced in these cells, as shown here by the
absence of Neu5Gc on PER.C6H-rEPO.
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